Drug profile · INN
bacampicillin hydrochloride
SPECTROBID
bacampicillin hydrochloride (SPECTROBID) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — bacampicillin hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bacampicillin hydrochloride (SPECTROBID) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Congress & event coverage
- PresentationTHMA Pharmacy Growth
Related & competitor drugs
Frequently asked questions
What is bacampicillin hydrochloride?
bacampicillin hydrochloride (SPECTROBID) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bacampicillin hydrochloride?
SPECTROBID is a marketed brand name for bacampicillin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bacampicillin hydrochloride?
bacampicillin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.